Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business https://lnkd.in/gEVjG72k Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for $44 million upfront. The Los Angeles-based company began looking for [...]
Los Angeles Biotech Networks’ Post
More Relevant Posts
-
Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business https://lnkd.in/gJs5gZu9 Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for $44 million upfront. The Los Angeles-based company began looking for [...]
-
Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business https://lnkd.in/gEVjG72k Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for $44 million upfront. The Los Angeles-based company began looking for [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News
-
Today, we are excited to announce an expansion to its strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG). This new collaboration builds upon the partnership initiated in January 2024, focusing on the discovery of a highly selective oral SMARCA2 small molecule proteolysis targeting chimera (PROTAC). Under the expanded agreement, BridGene will leverage its PROTAC discovery engine in combination with Galapagos' expertise in selective ATPase small molecules. The collaboration aims to advance the molecule into a preclinical candidate, with Galapagos holding exclusive rights for further development and commercialization. Galapagos will provide BridGene with upfront and preclinical milestone payments, alongside additional payments based on clinical and commercial milestones, potentially bringing the total deal value to $159 million. BridGene is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Read more here: https://lnkd.in/g7NyGm-m #BridGeneBiosciences #GalapagosNV #StrategicCollaboration #PrecisionOncology #PROTAC #SMARCA2 #DrugDiscovery #OncologyResearch #BiotechPartnership #InnovativeMedicine #CancerTreatment #TargetedTherapy #ClinicalResearch #Chemoproteomics #Biotechnology #Pharmaceuticals #DrugDevelopment #SmallMoleculeDrugs #ProteinDegradation #BiotechNews
-
In #Biotech deals and news: 🤝 "Under the terms of the Novartis deal, Light Horse Therapeutics will receive a $25-million upfront payment and could earn up to $1 billion in R&D and sales milestones, plus royalties on any licensed therapeutics. The partnership aims to identify and develop first-in-class therapeutics using Light Horse's platform technology." 🔬 Initial focus stated to be in the #Oncology space 💲 Deal could be worth ~ $1B #Biotech #Innovation #RandD #VC #CorporateAffairs #Deals #Alliances #Licensing #Pharma #Healthcare
-
CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager https://lnkd.in/gMW56vQD CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash. In order to focus its resources on its lead antibody-drug conjugate (ADC) and an array [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Exclusive: Athena Countouriotis' Avenzo taps Shanghai biotech for ADC, adds new funds >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #pharma #biotech
-
PINOTBIO, Inc., a Korean biotech specializing in antibody-drug conjugate (ADC) platforms, has once again failed its third attempt to go public. Despite its strong partnerships and pipeline, the company was unable to meet the technical evaluation requirements for a special technology listing.
-
Thoughts on this? >> Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing
-
Another step on the pathway to broader use of organ on chip. The seminal work from the Emulate, Inc. team in our predictive validity study on human liver chips paved the way for this exciting development! #organonchip #liverchip #NAMs
ANNOUNCEMENT: We're excited to share that the Emulate Liver-Chip has been accepted into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program—the first Organ-on-a-Chip technology to achieve this milestone. With this acceptance, the Liver-Chip will receive FDA support in the journey towards becoming a qualified Drug Development Tool (DDT) for predicting the safety of small-molecule drug candidates during preclinical testing. We are excited to begin collaborating with the FDA to develop a qualification plan, marking the next step in the three-stage DDT-qualification process. Participation in this program is a major part of our commitment to advancing Organ-on-a-Chip technology and improving predictivity and safety in drug development. Learn more about the ISTAND program: https://hubs.ly/Q02Q2_WF0
-
📰We're excited to announce that Vevo Therapeutics has partnered with the Parse GigaLab to generate the world’s largest single cell dataset to date, totaling 100 million cells! “This project demonstrates the GigaLab’s ability to deliver speed, quality, and immense scalability,” said Alex Rosenberg, CEO and Co-founder of Parse Biosciences. “We are incredibly excited to bring the power of GigaLab to Vevo and other biopharma partners, enabling groundbreaking discoveries and advancing drug development.” Read the full press release: https://parse.bio/41fZbth
-
